Veracyte (NASDAQ:VCYT) Announces Quarterly Earnings Results

Veracyte (NASDAQ:VCYT) issued its earnings results on Tuesday. The biotechnology company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.18, Briefing.com reports. The business had revenue of $139.07 million during the quarter, compared to analyst estimates of $130.36 million. Veracyte had a return on equity of 8.05% and a net margin of 12.83%.Veracyte’s revenue for the quarter was up 21.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.31 earnings per share.

Here are the key takeaways from Veracyte’s conference call:

• Veracyte delivered a strong Q1 with $139.1M total revenue (up 21% YoY), testing revenue of $135.1M (+26%), adjusted EBITDA of $42.8M (30.8% margin), and raised 2026 revenue guidance to $582M–$592M with adjusted EBITDA >26%.
• The Decipher franchise remains the primary growth engine—~28,000 tests in Q1 (+24% YoY), ~30% growth in high‑risk categories, and multiple Phase III studies (GUIDANCE, ENZAMET, PredictRT) and NCCN inclusion supporting longer‑term uptake.
• Afirma volumes improved to ~17,200 tests (+12% YoY) after the full transition to the V2 transcriptome, which materially reduced no‑result rates (adding ~400 bps to volume) and contributed to margin improvement.
• Two upcoming launches—Prosigna LDT (OPTIMA data at ASCO; commercial mid‑year) and TruMRD in muscle‑invasive bladder cancer (launch by end of Q2)—are positioned as major catalysts, but commercial impact is contingent on trial readouts, guideline/reimbursement decisions and adoption.
• Strong cash generation ($35.2M from operations; $439.1M cash/short‑term investments) and improved gross margins (non‑GAAP 75.7%) provide flexibility to fund R&D, commercial scale-up and selective M&A aligned with the company’s oncology focus.

Veracyte Stock Performance

VCYT stock traded up $8.47 on Wednesday, reaching $41.44. The company’s stock had a trading volume of 1,631,566 shares, compared to its average volume of 879,231. The business has a fifty day simple moving average of $33.33 and a two-hundred day simple moving average of $38.16. Veracyte has a 12-month low of $22.61 and a 12-month high of $50.71. The firm has a market cap of $3.31 billion, a PE ratio of 50.20 and a beta of 1.89.

Key Headlines Impacting Veracyte

Here are the key news stories impacting Veracyte this week:

• Positive Sentiment: Q1 beat on both EPS and revenue — Veracyte reported $0.52 EPS vs. consensus $0.34 and revenue of $139.1M (up 21.5% YoY), a clear short-term catalyst driving optimism. Veracyte (VCYT) Beats Q1 Earnings and Revenue Estimates
• Positive Sentiment: Raised FY2026 revenue outlook — Veracyte updated revenue guidance to $582M–$592M vs. the $576.5M consensus, signaling better-than-expected top-line momentum. Veracyte Announces First Quarter 2026 Financial Results
• Positive Sentiment: Strong product-line performance — Management said Decipher and Afirma volumes surpassed expectations and exceeded profitability targets, supporting margin and revenue improvement. Company Press Release
• Positive Sentiment: Analyst sentiment and upside — Several analysts have raised forecasts/targets; one roundup highlights ~39% average upside from price targets, which can pull momentum into the stock. Wall Street Analysts Think Veracyte Could Surge
• Neutral Sentiment: TrueMRD launch is a watched catalyst — Investors are awaiting details/timing for TrueMRD (a potential recurring-revenue product); positive launch details could extend gains, but timing/uptake remain uncertain. Veracyte earnings loom: Investors watch for TrueMRD launch details
• Neutral Sentiment: Earnings call and slide deck available — The transcript and slides provide more color on margin drivers and product performance for those modeling forward results. Earnings Call Transcript Slide Deck
• Negative Sentiment: Valuation and volatility risk — The shares trade at a relatively high P/E (~48.6) and carry a beta near 1.9, so upside could be met with sharp swings if growth expectations slip. (Background market data)
• Negative Sentiment: Guidance gaps — The company emphasized revenue guidance but did not provide specific EPS guidance in its update, leaving some short-term earnings visibility incomplete. Earnings Release and Materials

Insiders Place Their Bets

In related news, CEO Marc Stapley sold 45,523 shares of the firm’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $35.97, for a total value of $1,637,462.31. Following the completion of the sale, the chief executive officer owned 357,554 shares of the company’s stock, valued at $12,861,217.38. This trade represents a 11.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Annie Mcguire sold 6,658 shares of the firm’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $35.55, for a total value of $236,691.90. Following the completion of the sale, the senior vice president directly owned 94,706 shares of the company’s stock, valued at $3,366,798.30. The trade was a 6.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 75,782 shares of company stock worth $2,722,097. Insiders own 1.40% of the company’s stock.

Institutional Trading of Veracyte

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. California State Teachers Retirement System lifted its stake in Veracyte by 0.8% in the second quarter. California State Teachers Retirement System now owns 71,095 shares of the biotechnology company’s stock worth $1,922,000 after acquiring an additional 566 shares during the period. O Shaughnessy Asset Management LLC raised its holdings in Veracyte by 7.9% in the fourth quarter. O Shaughnessy Asset Management LLC now owns 7,894 shares of the biotechnology company’s stock worth $332,000 after purchasing an additional 576 shares in the last quarter. Smartleaf Asset Management LLC raised its holdings in Veracyte by 159.8% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,104 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 679 shares in the last quarter. Xponance LLC raised its holdings in Veracyte by 12.1% in the fourth quarter. Xponance LLC now owns 6,871 shares of the biotechnology company’s stock worth $289,000 after purchasing an additional 741 shares in the last quarter. Finally, Osaic Holdings Inc. raised its holdings in Veracyte by 21.0% in the fourth quarter. Osaic Holdings Inc. now owns 4,713 shares of the biotechnology company’s stock worth $198,000 after purchasing an additional 817 shares in the last quarter.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Guggenheim cut their target price on Veracyte from $50.00 to $45.00 and set a “buy” rating for the company in a research note on Monday, March 30th. Canaccord Genuity Group set a $42.00 price objective on Veracyte in a research note on Wednesday. UBS Group reissued a “buy” rating and set a $52.00 price objective on shares of Veracyte in a research note on Wednesday. Jefferies Financial Group initiated coverage on Veracyte in a research note on Monday, April 13th. They set a “buy” rating and a $45.00 price objective for the company. Finally, Morgan Stanley dropped their price objective on Veracyte from $48.00 to $37.00 and set an “underweight” rating for the company in a research note on Thursday, March 5th. Four analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $44.83.

Veracyte Company Profile

Veracyte, Inc is a genomic diagnostics company focused on improving diagnostic accuracy and patient care through advanced molecular testing. Founded in 2008 and headquartered in South San Francisco, California, the company develops and commercializes minimally invasive genomic tests that aid in the diagnosis of thyroid, lung and other diseases. Veracyte’s proprietary platform analyzes gene expression patterns in clinical samples to help physicians make more informed treatment decisions, reducing unnecessary surgeries and improving patient outcomes.

The company’s flagship product, the Afirma Genomic Sequencing Classifier, is designed to assess thyroid nodules with indeterminate cytology, helping clinicians distinguish benign from suspicious nodules.